Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MicroRNAs in diffuse large B-cell lymphoma.

Literature DB >> 26893730

MicroRNAs in diffuse large B-cell lymphoma.

Huiyun Ni¹, Rong Tong¹, Linqing Zou², Guoqi Song¹, William C Cho³.

Abstract

The aberrant expression of microRNAs (miRs) has a significant impact on the biological characteristics of lymphocytes, and is important in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). It has been demonstrated, using miR profiling and detecting distinct miR signatures, that certain miRs may accurately distinguish different subtypes and prognostic classifications of DLBCL, as well as distinguish DLBCL from other more indolent lymphomas, including follicular lymphoma. miRs are excellent biomarkers for cancer diagnosis and prognosis. In DLBCL, specific miR expression profiles in the tissues of patients are associated with prognosis and clinical outcome. Over the past decade, there has been substantial investigation concerning the pathogenetic, diagnostic and prognostic roles of miRs in DLBCL. The aim of the present review is to describe the aberrant expression of miRs in DLBCL, and the functions, potential clinical use and possible therapeutic targets of miRs in this disease.

Entities: Disease Gene Species

Keywords: diagnosis; diffuse large B-cell lymphoma; microRNAs; prognosis; regulator gene; therapeutic targets

Year: 2015 PMID： 26893730 PMCID： PMC4734178 DOI： 10.3892/ol.2015.4064

Source DB: PubMed Journal: Oncol Lett ISSN： 1792-1074 Impact factor: 2.967

86 in total

Review 1. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas.

Authors: Lorena Di Lisio; Nerea Martinez; Santiago Montes-Moreno; Miguel Piris-Villaespesa; Margarita Sanchez-Beato; Miguel A Piris
Journal: Blood Date: 2012-07-03 Impact factor: 22.113

2. Primitive erythropoiesis and megakaryopoiesis in the yolk sac are independent of c-myb.

Authors: Joanna Tober; Kathleen E McGrath; James Palis
Journal: Blood Date: 2008-01-03 Impact factor: 22.113

Review 3. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab.

Authors: Rohit Sud; Jonathan W Friedberg
Journal: Haematologica Date: 2008-12 Impact factor: 9.941

4. [Expression and clinical significance of miR-21 in diffuse large B cell lymphoma].

Authors: Chun-Hong Li; Rong Fu; Yi-Hao Wang; Wen-Jing Song; Er-Bao Ruan; Wen Qu; Hua-Quan Wang; Guo-Jin Wang; Jia Song; Xiao-Ming Wang; Yu-Hong Wu; Li-Min Xing; Hong Liu; Li-Juan Li; Jing Guan; Zong-Hong Shao
Journal: Zhongguo Shi Yan Xue Ye Xue Za Zhi Date: 2014-04

5. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.

Authors: Rachel E Culpin; Stephen J Proctor; Brian Angus; Stephen Crosier; John J Anderson; Tryfonia Mainou-Fowler
Journal: Int J Oncol Date: 2010-08 Impact factor: 5.650

6. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.

Authors: Haitao Bai; Ju Wei; Chong Deng; Xiaoyu Yang; Chun Wang; Rang Xu
Journal: Int J Hematol Date: 2012-12-30 Impact factor: 2.490

7. Altered MicroRNA expression in cervical carcinomas.

Authors: Jeong-Won Lee; Chel Hun Choi; Jung-Joo Choi; Young-Ae Park; Seung-Jun Kim; Seung Yong Hwang; Woo Young Kim; Tae-Joong Kim; Je-Ho Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531

8. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Authors: Cheng Li; Sang-Woo Kim; Deepak Rai; Aswani R Bolla; Siddharth Adhvaryu; Marsha C Kinney; Ryan S Robetorye; Ricardo C T Aguiar
Journal: Blood Date: 2009-03-10 Impact factor: 22.113

9. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.

Authors: Ayad Al-Katib; Alan A Arnold; Amro Aboukameel; Angela Sosin; Peter Smith; Anwar N Mohamed; Frances W Beck; Ramzi M Mohammad
Journal: Mol Cancer Date: 2010-09-01 Impact factor: 27.401

10. Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors: Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal: Nucleic Acids Res Date: 2005-11-27 Impact factor: 16.971

11 in total

1. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.

Authors: Eckart Meese; Friedrich A Grässer; Hiresh Ayoubian; Nicole Ludwig; Tobias Fehlmann; Jennifer Menegatti; Laura Gröger; Eleni Anastasiadou; Pankaj Trivedi; Andreas Keller
Journal: J Virol Date: 2019-01-17 Impact factor: 5.103

2. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.

Authors: Francesco Marchesi; Giulia Regazzo; Francesca Palombi; Irene Terrenato; Andrea Sacconi; Manuela Spagnuolo; Sara Donzelli; Mirella Marino; Cristiana Ercolani; Anna Di Benedetto; Giovanni Blandino; Gennaro Ciliberto; Andrea Mengarelli; Maria Giulia Rizzo
Journal: J Exp Clin Cancer Res Date: 2018-05-02

Review 3. Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma.

Authors: Gabrielle Bradshaw; Heidi G Sutherland; Larisa M Haupt; Lyn R Griffiths
Journal: Genes (Basel) Date: 2016-12-17 Impact factor: 4.096

4. Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma.

Authors: Qingyan Cui; Frank Vari; Alexandre S Cristino; Carlos Salomon; Gregory E Rice; Muhammed B Sabdia; Dominic Guanzon; Carlos Palma; Marina Mathew; Dipti Talaulikar; Sanjiv Jain; Erica Han; Mark S Hertzberg; Clare Gould; Pauline Crooks; Gayathri Thillaiyampalam; Colm Keane; Maher K Gandhi
Journal: Oncotarget Date: 2018-10-05

5. Effect of Plasma-Derived Exosomes of Refractory/Relapsed or Responsive Patients with Diffuse Large B-Cell Lymphoma on Natural Killer Cells Functions.

Authors: Nasrin Zare; S Haghayegh Haghjooy Javanmard; Valiollah Mehrzad; Nahid Eskandari; Ali Reza Andalib
Journal: Cell J Date: 2019-09-08 Impact factor: 2.479

6. Long Non-Coding RNAs Modulate Sjögren's Syndrome Associated Gene Expression and Are Involved in the Pathogenesis of the Disease.

Authors: Marzia Dolcino; Elisa Tinazzi; Claudio Vitali; Nicoletta Del Papa; Antonio Puccetti; Claudio Lunardi
Journal: J Clin Med Date: 2019-09-01 Impact factor: 4.241

7. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.

Authors: Maogui Hu; Xinchen Wang; Ning Liu; Kaiyang Ding; Guihong Zhang; Xiaosi Liu
Journal: Biosci Rep Date: 2021-07-30 Impact factor: 3.840